Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 34 positions · Total reported value $2.06B · Top-10 concentration 71.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.0% · 6 new · 5 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Venrock Adviser, LLC disclosed 34 equity positions with a combined reported value of $2.06B. The filing implies a focused portfolio: its ten largest positions account for 71.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ORKA ($345.52M), ERAS ($294.52M), SYRE ($221.28M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+33.9pp) and away from Other (-33.8pp).

Versus the prior quarter, Venrock Adviser, LLC opened 6 new positions, trimmed 5 and fully exited 5, a turnover rate of 41.0% of positions. The portfolio's overlap with the prior quarter was 72% of names.

The largest new positions opened in Q3 2026 were ANIX ($145.59M), VNDA ($32.42M), ARVN ($15.10M).

Of the 5 positions fully exited versus the prior quarter, the largest were APGE ($1.13B), ELVN ($26.71M), HELP ($25.46M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ANIX ANIXA BIOSCIENCES INC · $145.59M
  • VNDA VANDA PHARMACEUTICALS INC · $32.42M
  • ARVN ARVINAS INC · $15.10M
  • ENTX ENTERA BIO LTD · $14.86M
  • TLGYF TCGX ACQUISITION CORP · $3.75M
  • RACD RESEARCH ALLIANCE CORP IV · $3.60M

Fully Exited (vs previous quarter)

  • APGE APOGEE THERAPEUTICS INC · prev qtr: $1.13B
  • ELVN ENLIVEN THERAPEUTICS INC · prev qtr: $26.71M
  • HELP CYBIN INC · prev qtr: $25.46M
  • CTMX CYTOMX THERAPEUTICS INC. · prev qtr: $18.68M
  • RACC Research Alliance Corp Iii Ord Shs Cl A · prev qtr: $3.21M

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 33 US equity positions with a combined value of $3.30B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 33 positions · $3.30B reported value (Q2 2026)
  • Top 10 holdings = 80.4% of reported value
  • Largest position: APGE (APOGEE THERAPEUTICS INC) at 34.2%
  • Average position size: $99.94M

Sector Tilt

  • Health Care 65.7%
  • Financials 0.1%
  • (classified holdings cover 66% of value)

Quarterly Activity

  • Q2 2026: 4 new, 5 added, 5 reduced, 4 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.15M $345.52M 16.79%
16.79%
Hold
2 20.09M $294.52M 14.31%
14.31%
Add
3 2.49M $221.28M 10.75%
10.75%
Reduce
4 4.55M $145.59M 7.07%
7.07%
New
5 19.57M $100.97M 4.91%
4.91%
Add
6 10.35M $79.36M 3.86%
3.86%
Hold
7 3.60M $76.68M 3.73%
3.73%
Hold
8 822.02K $72.38M 3.52%
3.52%
Reduce
9 3.26M $67.08M 3.26%
3.26%
Hold
10 3.04M $58.04M 2.82%
2.82%
Hold
11 1.64M $52.58M 2.56%
2.56%
Hold
12 3.21M $51.40M 2.50%
2.50%
Hold
13 3.22M $45.25M 2.20%
2.20%
Hold
14 5.50M $44.51M 2.16%
2.16%
Add
15 1.55M $42.01M 2.04%
2.04%
Reduce
16 2.94M $39.66M 1.93%
1.93%
Reduce
17 2.17M $35.02M 1.70%
1.70%
Hold
18 1.63M $32.42M 1.57%
1.57%
New
19 2.13M $31.13M 1.51%
1.51%
Hold
20 7.45M $28.07M 1.36%
1.36%
Add
21 6.43M $26.77M 1.30%
1.30%
Hold
22 7.64M $22.17M 1.08%
1.08%
Add
23 1.38M $21.18M 1.03%
1.03%
Hold
24 632.93K $20.37M 0.99%
0.99%
Hold
25 625.00K $20.18M 0.98%
0.98%
Hold
26 1.95M $15.10M 0.73%
0.73%
New
27 8.70M $14.87M 0.72%
0.72%
Hold
28 5.11M $14.86M 0.72%
0.72%
New
29 2.04M $14.55M 0.71%
0.71%
Hold
30 500.00K $12.77M 0.62%
0.62%
Hold
31 443.43K $4.39M 0.21%
0.21%
Reduce
32 300.00K $3.75M 0.18%
0.18%
New
33 300.00K $3.60M 0.17%
0.17%
New
34 133.38K $181.39K 0.01%
0.01%
Add

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Historical Backtest (10 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 2.5 · Top-10 turnover 19%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% RYZB · APGE · PHVS · VRDN · FDMT · MRUS · CABA · KALV · SYRE · ELVN APGE · FDMT · OCUL · SYRE · MRUS · PHVS · KALV · ELVN · VRDN · DNTH
2024-Q2 90% 90% 90% APGE · FDMT · OCUL · PHVS · KALV · MRUS · SYRE · ELVN · DNTH · VRDN APGE · ELVN · FDMT · OCUL · DYN · MRUS · KALV · PHVS · SYRE · DNTH
2024-Q3 70% 70% 70% APGE · ELVN · FDMT · OCUL · KALV · DYN · MRUS · SYRE · PHVS · DNTH APGE · OCUL · ELVN · VRDN · APLT · SYRE · DYN · ORKA · KALV · PHVS
2024-Q4 90% 90% 90% APGE · OCUL · ELVN · VRDN · APLT · SYRE · DYN · ORKA · KALV · PHVS APGE · OCUL · ELVN · PRAX · VRDN · ORKA · SYRE · PHVS · KALV · DYN
2025-Q1 90% 90% 90% APGE · OCUL · ELVN · PRAX · VRDN · ORKA · SYRE · PHVS · KALV · DYN APGE · MTSR · OCUL · ELVN · KALV · VRDN · PHVS · SYRE · ORKA · PRAX
2025-Q2 90% 90% 90% APGE · MTSR · OCUL · ELVN · KALV · VRDN · PHVS · ORKA · SYRE · PRAX APGE · OCUL · MTSR · ELVN · KALV · ORIC · VRDN · ORKA · SYRE · PHVS
2025-Q3 80% 80% 80% APGE · OCUL · MTSR · ELVN · KALV · ORIC · VRDN · ORKA · SYRE · PHVS APGE · MTSR · OCUL · CDTX · VRDN · KALV · ORKA · ORIC · ELVN · COGT
2025-Q4 60% 60% 60% APGE · MTSR · OCUL · CDTX · ORIC · VRDN · KALV · ORKA · ELVN · COGT APGE · ORKA · VRDN · SYRE · KALV · OCUL · SVRA · COGT · ERAS · CTMX
2026-Q1 70% 70% 70% APGE · SYRE · ORKA · VRDN · KALV · SVRA · OCUL · MAZE · CTMX · ERAS APGE · ERAS · ORKA · SYRE · KALV · DNTH · DMRA · OCUL · COGT · VRDN
2026-Q2 ★ 80% 80% 80% APGE · ERAS · ORKA · SYRE · KALV · DNTH · DMRA · OCUL · VRDN · SVRA APGE · ORKA · ERAS · SYRE · DNTH · OCUL · DMRA · SVRA · JBIO · COGT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings1 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return+24.72%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+41.74%vs benchmark
Barra annualised vol81.2%Model estimate
Realised vol50.6%Annualised in window
Weighted beta1.08Raw exposure
Factor / specific risk32% / 68%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)75.891.8107.7123.6139.510-0110-2311-16Venrock Adviser, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+24.72%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+41.74%Portfolio − benchmark
Arithmetic return sum+23.75%Difference vs compounded is the cross term
Weighted raw beta1.08Weighted holding betas
Realised volatility (annualised)50.63%Daily returns in window
Barra model volatility (annualised)81.19%Factor + specific
Factor share of variance32.0%Barra factors
Specific share of variance68.0%Stock residuals
Reported value$42.0M13F long US equity

2. Return attribution

The +23.75% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -0.33% -1.4%
Momentum & Growth 3 +0.07% 0.3%
Volatility & Tail Risk 7 +4.60% 19.4%
Industry 12 +6.98% 29.4%
Specific 1 +12.42% 52.3%
Return attribution (style + industry, %)-28.1-14.1+0.0+14.1+28.1Growth-0.62Beta+0.97Momentum+1.19Amihud Illiquidity-1.23Leverage (Downside Vol)+1.92Max Drawdown+3.06Non-linear Size+3.10Size+3.23Mid Cap-5.17Residual Volatility+6.72Health Care+6.98Skewness-11.71Historical Volatility-22.39Kurtosis+26.02
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +3.47 +7.51% +26.02% 109.5%
Specific Specific — — +12.42% 52.3%
Health Care Industry +1.00 +6.98% +6.98% 29.4%
Residual Volatility Style +2.04 +3.29% +6.72% 28.3%
Size Style -1.66 -1.95% +3.23% 13.6%
Non-linear Size Style +3.07 +1.01% +3.10% 13.0%
Max Drawdown Style -1.74 -1.76% +3.06% 12.9%
Leverage (Downside Vol) Style -1.12 -1.71% +1.92% 8.1%
Momentum Style -0.30 -4.00% +1.19% 5.0%
Beta Style +0.22 +4.44% +0.97% 4.1%
Turnover Style +0.06 -4.80% -0.31% -1.3%
Short-term Reversal Style -0.57 +0.87% -0.50% -2.1%
Growth Style -0.36 +1.75% -0.62% -2.6%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -5.2%
Mid Cap Style +2.67 -1.94% -5.17% -21.8%
Skewness Style +2.66 -4.39% -11.71% -49.3%
Historical Volatility Style +1.60 -14.00% -22.39% -94.2%

3. Risk attribution

Annualised volatility is 81.19%; factor risk explains 32.0% of variance and specific risk 68.0%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-73.4-36.7+0.0+36.7+73.4Residual Volatility-1.18Leverage (Downside Vol)-0.39Amihud Illiquidity+0.86Kurtosis+1.00Growth+1.15Size+1.55Short-term Reversal+1.77Non-linear Size+3.31Mid Cap+3.79Health Care+4.34Skewness+4.92Historical Volatility+5.13Max Drawdown+6.16Specific+67.96
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 68.0% +55.18% 55.2%
Max Drawdown Style -1.74 6.2% +5.00% 5.0%
Historical Volatility Style +1.60 5.1% +4.16% 4.2%
Skewness Style +2.66 4.9% +3.99% 4.0%
Health Care Industry +1.00 4.3% +3.52% 3.5%
Mid Cap Style +2.67 3.8% +3.08% 3.1%
Non-linear Size Style +3.07 3.3% +2.69% 2.7%
Short-term Reversal Style -0.57 1.8% +1.44% 1.4%
Size Style -1.66 1.6% +1.26% 1.3%
Growth Style -0.36 1.1% +0.94% 0.9%
Kurtosis Style +3.47 1.0% +0.81% 0.8%
Amihud Illiquidity Style +2.75 0.9% +0.70% 0.7%
Beta Style +0.22 -0.2% -0.19% -0.2%
Leverage (Downside Vol) Style -1.12 -0.4% -0.32% -0.3%
Residual Volatility Style +2.04 -1.2% -0.96% -1.0%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.3-0.70.92.44.0Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.22 +1.29 -1.08
Momentum -0.30 +0.72 -1.02
Short-term Reversal -0.57 -0.64 +0.08
Residual Volatility +2.04 -0.40 +2.44
Historical Volatility +1.60 +0.86 +0.74
Liquidity +0.13 +0.11 +0.01
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +0.06 +0.21 -0.14
Growth -0.36 +0.58 -0.94
Leverage (Downside Vol) -1.12 +0.14 -1.26
Skewness +2.66 +0.24 +2.43
Kurtosis +3.47 +0.21 +3.25
Max Drawdown -1.74 -0.08 -1.66

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Health Care 100.0% 1.7% +24.72% +8.29% +24.98% +0.28% +16.15% +24.58%
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Total +23.98% +16.12% +0.31% +40.42%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
MAZE MAZE THERAPEUTICS INC Health Care 100.00% +24.72% +24.72% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 MAZE Health Care 100.00% +24.72% +24.72%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +24.72%, versus -17.01% for the QQQ synthetic benchmark — an excess of +41.74%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +26.02%, Health Care +6.98%, Residual Volatility +6.72%; the largest drags came from Historical Volatility -22.39%, Skewness -11.71%, Mid Cap -5.17%. Specific (stock-level) return contributed +12.42%.
  3. Risk attribution: Barra model volatility is 81.19% annualised; factor risk explains 32% of variance and specific risk 68%. The largest factor risk sources are Max Drawdown 6.2%, Historical Volatility 5.1%, Skewness 4.9%.
  4. Style tilt: size -1.66, momentum -0.30, volatility +1.60, liquidity +0.13; the weighted raw beta is 1.08. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +16.12% and interaction +0.31%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Venrock Adviser, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Venrock Adviser, LLC reported 34 equity positions worth $2.06B in aggregate; its largest disclosed positions were ORKA ($345.52M), ERAS ($294.52M), SYRE ($221.28M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $2.06B of long equity holdings across 34 positions as of 2026-Q3. Top-10 holdings account for 71.0% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →